BRPI0710979A2 - composto, composição farmacêutica, uso de um composto, métodos para a inibição de relaxamentos do esfìncter esofágico inferior transitórios e para o tratamento ou prevenção de doença e de condição, e, combinação - Google Patents

composto, composição farmacêutica, uso de um composto, métodos para a inibição de relaxamentos do esfìncter esofágico inferior transitórios e para o tratamento ou prevenção de doença e de condição, e, combinação Download PDF

Info

Publication number: BRPI0710979A2
Authority: BR; Brazil
Prior art keywords: methyl; phenyl; pyrrolidin; isoxazol; triazol
Prior art date: 2006-05-05

Application number

BRPI0710979-2A

Other languages

English (en)

Portuguese (pt)

Inventor

Andreas Wallberg

Karolina Nilsson

Bjoern Holm

Mats Nagard

Kenneth Granberg

Abdelmalik Slassi

Louise Edwards

Methvin Isaac

Tao Xin

Tomislav Stefanac

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-05

Filing date

2007-04-25

Publication date

2011-05-31

2007-04-25 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-05-31 Publication of BRPI0710979A2 publication Critical patent/BRPI0710979A2/pt

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 158
238000011282 treatment Methods 0.000 title claims abstract description 38
238000000034 method Methods 0.000 title claims abstract description 29
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
230000005764 inhibitory process Effects 0.000 title claims abstract description 6
210000000111 lower esophageal sphincter Anatomy 0.000 title claims description 10
230000001052 transient effect Effects 0.000 title claims description 8
230000006806 disease prevention Effects 0.000 title abstract description 3
238000002560 therapeutic procedure Methods 0.000 claims abstract description 8
-1 5- { (R) -2- [2- (3-Chloro-phenyl) -2H-tetrazol-5-yl] -pyrrolidin-1-yl} -4-methyl-4H- [1,2,4] triazol-3-one Chemical compound 0.000 claims description 49
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 24
239000001257 hydrogen Substances 0.000 claims description 24
239000002253 acid Substances 0.000 claims description 23
125000000217 alkyl group Chemical group 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 16
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 15
239000011737 fluorine Chemical group 0.000 claims description 15
229910052731 fluorine Chemical group 0.000 claims description 15
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
150000002431 hydrogen Chemical class 0.000 claims description 14
230000002401 inhibitory effect Effects 0.000 claims description 14
230000002265 prevention Effects 0.000 claims description 14
125000003545 alkoxy group Chemical group 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 11
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 9
150000002367 halogens Chemical group 0.000 claims description 9
208000002193 Pain Diseases 0.000 claims description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
230000009858 acid secretion Effects 0.000 claims description 7
125000004093 cyano group Chemical group *C#N 0.000 claims description 6
208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
230000036407 pain Effects 0.000 claims description 6
239000000460 chlorine Substances 0.000 claims description 5
150000004677 hydrates Chemical class 0.000 claims description 5
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 4
125000001188 haloalkyl group Chemical group 0.000 claims description 4
125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
108010029485 Protein Isoforms Proteins 0.000 claims description 3
102000001708 Protein Isoforms Human genes 0.000 claims description 3
229910052801 chlorine Inorganic materials 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 2
229960001380 cimetidine Drugs 0.000 claims description 2
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
229960004770 esomeprazole Drugs 0.000 claims description 2
SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 2
229960003174 lansoprazole Drugs 0.000 claims description 2
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 2
229960000381 omeprazole Drugs 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
229960005019 pantoprazole Drugs 0.000 claims description 2
229960004157 rabeprazole Drugs 0.000 claims description 2
YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 2
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 2
229960000620 ranitidine Drugs 0.000 claims description 2
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 11
230000003287 optical effect Effects 0.000 claims 5
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 4
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
150000004702 methyl esters Chemical class 0.000 claims 2
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims 2
HKQZYRFLGPKADF-CYBMUJFWSA-N (2R)-2-[5-(2-fluoro-5-methylphenyl)-1,2-oxazol-3-yl]pyrrolidine-1-carboxylic acid Chemical compound FC1=C(C=C(C=C1)C)C1=CC(=NO1)[C@@H]1N(CCC1)C(=O)O HKQZYRFLGPKADF-CYBMUJFWSA-N 0.000 claims 1
CSBNWNRWVNVSFJ-GFCCVEGCSA-N (2r)-2-[2-(3-cyanophenyl)tetrazol-5-yl]-n-methylpyrrolidine-1-carbothioamide Chemical compound CNC(=S)N1CCC[C@@H]1C1=NN(C=2C=C(C=CC=2)C#N)N=N1 CSBNWNRWVNVSFJ-GFCCVEGCSA-N 0.000 claims 1
IBCFHTPHKRBAFX-CYBMUJFWSA-N (2r)-2-[5-(5-chloro-2-fluorophenyl)-1,2-oxazol-3-yl]-n-methylpyrrolidine-1-carbothioamide Chemical compound CNC(=S)N1CCC[C@@H]1C1=NOC(C=2C(=CC=C(Cl)C=2)F)=C1 IBCFHTPHKRBAFX-CYBMUJFWSA-N 0.000 claims 1
PXFUQACFOVCSKG-UHFFFAOYSA-N 1-methyl-6-oxopyridazine-4-carbohydrazide Chemical compound CN1N=CC(C(=O)NN)=CC1=O PXFUQACFOVCSKG-UHFFFAOYSA-N 0.000 claims 1
PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
VXGRXJXPHIASRF-UHFFFAOYSA-N [2,2,2-trichloro-1-(5-chloro-2-fluorophenyl)ethyl] acetate Chemical compound CC(=O)OC(C(Cl)(Cl)Cl)C1=CC(Cl)=CC=C1F VXGRXJXPHIASRF-UHFFFAOYSA-N 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 1
229950007395 leminoprazole Drugs 0.000 claims 1
VGIMHPGWRYIFSM-CYBMUJFWSA-N tert-butyl (2r)-2-[2-(3-chlorophenyl)tetrazol-5-yl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C1=NN(C=2C=C(Cl)C=CC=2)N=N1 VGIMHPGWRYIFSM-CYBMUJFWSA-N 0.000 claims 1
KMGRYFZHFRUUTE-MRXNPFEDSA-N tert-butyl (2r)-2-[5-(3-cyanophenyl)-1,2-oxazol-3-yl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C1=NOC(C=2C=C(C=CC=2)C#N)=C1 KMGRYFZHFRUUTE-MRXNPFEDSA-N 0.000 claims 1
BVMHRFRFEWARDM-MRXNPFEDSA-N tert-butyl (2r)-2-[5-(3-methylphenyl)-1,2-oxazol-3-yl]pyrrolidine-1-carboxylate Chemical compound CC1=CC=CC(C=2ON=C(C=2)[C@@H]2N(CCC2)C(=O)OC(C)(C)C)=C1 BVMHRFRFEWARDM-MRXNPFEDSA-N 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 54
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 50
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 49
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
239000000203 mixture Substances 0.000 description 35
238000005160 1H NMR spectroscopy Methods 0.000 description 34
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
239000000047 product Substances 0.000 description 32
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
238000006243 chemical reaction Methods 0.000 description 27
239000011541 reaction mixture Substances 0.000 description 24
239000002904 solvent Substances 0.000 description 24
102000016193 Metabotropic glutamate receptors Human genes 0.000 description 23
108010010914 Metabotropic glutamate receptors Proteins 0.000 description 23
239000007787 solid Substances 0.000 description 23
108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 21
102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 21
230000004913 activation Effects 0.000 description 21
208000035475 disorder Diseases 0.000 description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
235000019439 ethyl acetate Nutrition 0.000 description 17
238000007792 addition Methods 0.000 description 16
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
230000000694 effects Effects 0.000 description 12
239000000243 solution Substances 0.000 description 12
238000003756 stirring Methods 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
239000012044 organic layer Substances 0.000 description 10
239000011734 sodium Substances 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
210000004556 brain Anatomy 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
230000001404 mediated effect Effects 0.000 description 9
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
230000009466 transformation Effects 0.000 description 9
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
239000012267 brine Substances 0.000 description 8
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
210000002569 neuron Anatomy 0.000 description 8
239000003921 oil Substances 0.000 description 8
239000000843 powder Substances 0.000 description 8
229960003010 sodium sulfate Drugs 0.000 description 8
229910052938 sodium sulfate Inorganic materials 0.000 description 8
235000011152 sodium sulphate Nutrition 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
229930195712 glutamate Natural products 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 7
238000010992 reflux Methods 0.000 description 7
238000000844 transformation Methods 0.000 description 7
241000282414 Homo sapiens Species 0.000 description 6
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
150000001299 aldehydes Chemical class 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000000284 extract Substances 0.000 description 6
238000001802 infusion Methods 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical group OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
239000007995 HEPES buffer Substances 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000000556 agonist Substances 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000011575 calcium Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
229960000367 inositol Drugs 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
239000007858 starting material Substances 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 5
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
208000018522 Gastrointestinal disease Diseases 0.000 description 4
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
230000005284 excitation Effects 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
150000002545 isoxazoles Chemical class 0.000 description 4
230000000926 neurological effect Effects 0.000 description 4
150000002825 nitriles Chemical class 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000012071 phase Substances 0.000 description 4
235000021317 phosphate Nutrition 0.000 description 4
239000000523 sample Substances 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108091006146 Channels Proteins 0.000 description 3
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
208000019695 Migraine disease Diseases 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
208000025966 Neurological disease Diseases 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
102000014384 Type C Phospholipases Human genes 0.000 description 3
108010079194 Type C Phospholipases Proteins 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
125000005620 boronic acid group Chemical class 0.000 description 3
239000007975 buffered saline Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 3
230000007423 decrease Effects 0.000 description 3
206010015037 epilepsy Diseases 0.000 description 3
230000002964 excitative effect Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
239000010410 layer Substances 0.000 description 3
210000001853 liver microsome Anatomy 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 description 3
FXXHEBJCBBMISD-UHFFFAOYSA-N methyl 1-methyl-6-oxopyridine-3-carboxylate Chemical compound COC(=O)C=1C=CC(=O)N(C)C=1 FXXHEBJCBBMISD-UHFFFAOYSA-N 0.000 description 3
206010027599 migraine Diseases 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
230000037361 pathway Effects 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
208000020016 psychiatric disease Diseases 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
230000002336 repolarization Effects 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
201000000980 schizophrenia Diseases 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
235000017550 sodium carbonate Nutrition 0.000 description 3
235000011121 sodium hydroxide Nutrition 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 3
CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
JQAOHGMPAAWWQO-MRVPVSSYSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCC[C@@H]1C(O)=O JQAOHGMPAAWWQO-MRVPVSSYSA-N 0.000 description 2
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
RGZCKPXTNJAWMR-UHFFFAOYSA-N 1-methyl-6-oxopyridine-3-carboxylic acid Chemical compound CN1C=C(C(O)=O)C=CC1=O RGZCKPXTNJAWMR-UHFFFAOYSA-N 0.000 description 2
MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 2
KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
SAQSTQBVENFSKT-UHFFFAOYSA-M TCA-sodium Chemical compound [Na+].[O-]C(=O)C(Cl)(Cl)Cl SAQSTQBVENFSKT-UHFFFAOYSA-M 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
230000037007 arousal Effects 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000010949 copper Substances 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
WHZLYDJNIUHZCS-UHFFFAOYSA-N disodium 2-methylpropan-2-olate Chemical compound CC(C)([O-])C.[Na+].[Na+].CC(C)([O-])C WHZLYDJNIUHZCS-UHFFFAOYSA-N 0.000 description 2
238000004821 distillation Methods 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
FVBGGKYTKXFLOV-UHFFFAOYSA-N ethyl pyridazine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NN=C1 FVBGGKYTKXFLOV-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000011630 iodine Substances 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000011068 loading method Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
150000002923 oximes Chemical class 0.000 description 2
230000007170 pathology Effects 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000001242 postsynaptic effect Effects 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
239000000276 potassium ferrocyanide Substances 0.000 description 2
230000003518 presynaptic effect Effects 0.000 description 2
150000003138 primary alcohols Chemical class 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000002553 single reaction monitoring Methods 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000012453 solvate Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
208000003663 ventricular fibrillation Diseases 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
239000011701 zinc Substances 0.000 description 2
OAWXZFGKDDFTGS-SCSAIBSYSA-N (2r)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-SCSAIBSYSA-N 0.000 description 1
SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
GYMLKVABUBRXLQ-UHFFFAOYSA-N 1,2-dimethyl-6-oxopyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(=O)N1C GYMLKVABUBRXLQ-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
JMLWXCJXOYDXRN-UHFFFAOYSA-N 1-chloro-3-iodobenzene Chemical compound ClC1=CC=CC(I)=C1 JMLWXCJXOYDXRN-UHFFFAOYSA-N 0.000 description 1
MTMSVCHXICINDR-UHFFFAOYSA-N 1-methyl-2-oxopyridine-4-carbohydrazide Chemical compound CN1C=CC(C(=O)NN)=CC1=O MTMSVCHXICINDR-UHFFFAOYSA-N 0.000 description 1
WCGPQGBPGIDIKC-UHFFFAOYSA-N 1-methyl-6-oxopyridine-3-carbohydrazide Chemical compound CN1C=C(C(=O)NN)C=CC1=O WCGPQGBPGIDIKC-UHFFFAOYSA-N 0.000 description 1
ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
VVVOJODFBWBNBI-UHFFFAOYSA-N 2,5-difluorobenzaldehyde Chemical compound FC1=CC=C(F)C(C=O)=C1 VVVOJODFBWBNBI-UHFFFAOYSA-N 0.000 description 1
AFJMHVBJEYSZIN-UHFFFAOYSA-N 2,6-dimethoxypyrimidine-4-carbohydrazide Chemical compound COC1=CC(C(=O)NN)=NC(OC)=N1 AFJMHVBJEYSZIN-UHFFFAOYSA-N 0.000 description 1
YJVQWSWHMZHVEW-UHFFFAOYSA-N 2-(2,2-dichloroethenyl)-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(C=C(Cl)Cl)=C1 YJVQWSWHMZHVEW-UHFFFAOYSA-N 0.000 description 1
HBDKFZNDMVLSHM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfinyl)-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1S(=O)CC1=CC=CC=N1 HBDKFZNDMVLSHM-UHFFFAOYSA-N 0.000 description 1
FBCWFOLOHWOWFX-UHFFFAOYSA-N 2-methoxy-2-methylpropane;hydrate Chemical compound O.COC(C)(C)C FBCWFOLOHWOWFX-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical class NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 description 1
QEZDMZVLNWSJSA-UHFFFAOYSA-N 3-(2-trimethylsilylethynyl)benzonitrile Chemical compound C[Si](C)(C)C#CC1=CC=CC(C#N)=C1 QEZDMZVLNWSJSA-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
GVGYEFKIHJTNQZ-UHFFFAOYSA-N 3-benzoyloxy-8-methyl-8-azoniabicyclo[3.2.1]octane-4-carboxylate Chemical compound CN1C(C2)CCC1C(C(O)=O)C2OC(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-UHFFFAOYSA-N 0.000 description 1
BGARPMGQRREXLN-UHFFFAOYSA-N 3-iodobenzonitrile Chemical compound IC1=CC=CC(C#N)=C1 BGARPMGQRREXLN-UHFFFAOYSA-N 0.000 description 1
WATXAIVBMQBTGJ-UHFFFAOYSA-N 3-piperidin-1-yl-1,2-oxazole Chemical compound C1CCCCN1C1=NOC=C1 WATXAIVBMQBTGJ-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
MMDFKVYPOQFQHP-UHFFFAOYSA-N 4-methyl-1h-pyridazin-6-one Chemical compound CC=1C=NNC(=O)C=1 MMDFKVYPOQFQHP-UHFFFAOYSA-N 0.000 description 1
ARSYSLIDXQXNMK-UHFFFAOYSA-N 4-methylbenzenesulfonic acid hydrofluoride Chemical compound F.CC1=CC=C(S(O)(=O)=O)C=C1 ARSYSLIDXQXNMK-UHFFFAOYSA-N 0.000 description 1
VRCWSYYXUCKEED-UHFFFAOYSA-N 6-Hydroxypicolinic acid Chemical compound OC(=O)C1=CC=CC(=O)N1 VRCWSYYXUCKEED-UHFFFAOYSA-N 0.000 description 1
BLHCMGRVFXRYRN-UHFFFAOYSA-N 6-hydroxynicotinic acid Chemical compound OC(=O)C1=CC=C(O)N=C1 BLHCMGRVFXRYRN-UHFFFAOYSA-N 0.000 description 1
PSMIHCDKMNXTAY-UHFFFAOYSA-N 6-oxo-1h-pyridazine-4-carboxylic acid Chemical compound OC(=O)C=1C=NNC(=O)C=1 PSMIHCDKMNXTAY-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
208000020706 Autistic disease Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010004663 Biliary colic Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
YYQOBENRSYYGHA-UHFFFAOYSA-L CC([O-])=O.CC([O-])=O.ClC1=CC=CC([I+2])=C1 Chemical compound CC([O-])=O.CC([O-])=O.ClC1=CC=CC([I+2])=C1 YYQOBENRSYYGHA-UHFFFAOYSA-L 0.000 description 1
101100181929 Caenorhabditis elegans lin-3 gene Proteins 0.000 description 1
101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
206010017999 Gastrointestinal pain Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
108010078321 Guanylate Cyclase Proteins 0.000 description 1
102000014469 Guanylate cyclase Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020853 Hypertonic bladder Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
241000764238 Isis Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
201000008197 Laryngitis Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
102100037611 Lysophospholipase Human genes 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
102000011420 Phospholipase D Human genes 0.000 description 1
108090000553 Phospholipase D Proteins 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
206010062519 Poor quality sleep Diseases 0.000 description 1
206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010067171 Regurgitation Diseases 0.000 description 1
206010038419 Renal colic Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
208000027520 Somatoform disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
208000009205 Tinnitus Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
LRIUKPUCKCECPT-UHFFFAOYSA-N [hydroxy(phenyl)-$l^{3}-iodanyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OI(O)C1=CC=CC=C1 LRIUKPUCKCECPT-UHFFFAOYSA-N 0.000 description 1
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
229910052787 antimony Inorganic materials 0.000 description 1
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
150000001502 aryl halides Chemical class 0.000 description 1
238000006254 arylation reaction Methods 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
JHXKRIRFYBPWGE-UHFFFAOYSA-K bismuth chloride Chemical compound Cl[Bi](Cl)Cl JHXKRIRFYBPWGE-UHFFFAOYSA-K 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
JJPIQQGMZUADGD-UHFFFAOYSA-L copper;3-phenylbutanoate Chemical compound [Cu+2].[O-]C(=O)CC(C)C1=CC=CC=C1.[O-]C(=O)CC(C)C1=CC=CC=C1 JJPIQQGMZUADGD-UHFFFAOYSA-L 0.000 description 1
GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
229940076286 cupric acetate Drugs 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003596 drug target Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
LNKWUQZNSSCTCQ-UHFFFAOYSA-N ethyl 1-methyl-6-oxopyridazine-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C)C(=O)C=1 LNKWUQZNSSCTCQ-UHFFFAOYSA-N 0.000 description 1
SFWONOUKADVLTA-UHFFFAOYSA-M ethyl 1-methylpyridin-1-ium-4-carboxylate;iodide Chemical compound [I-].CCOC(=O)C1=CC=[N+](C)C=C1 SFWONOUKADVLTA-UHFFFAOYSA-M 0.000 description 1
MYHCWGDFZQZTQA-UHFFFAOYSA-N ethyl 4,4-dimethoxy-3-methylbut-2-enoate Chemical compound CCOC(=O)C=C(C)C(OC)OC MYHCWGDFZQZTQA-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
MCRPKBUFXAKDKI-UHFFFAOYSA-N ethyl pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1 MCRPKBUFXAKDKI-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical class [H]C#C* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
238000010304 firing Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000012739 integrated shape imaging system Methods 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
229940028435 intralipid Drugs 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
230000001057 ionotropic effect Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
238000000622 liquid--liquid extraction Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000027928 long-term synaptic potentiation Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000021073 macronutrients Nutrition 0.000 description 1
OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical class [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
NDGHVBDLRZUIHF-GFCCVEGCSA-N methyl (2r)-2-[2-(3-chlorophenyl)tetrazol-5-yl]-n-methylpyrrolidine-1-carboximidothioate Chemical compound CSC(=NC)N1CCC[C@@H]1C1=NN(C=2C=C(Cl)C=CC=2)N=N1 NDGHVBDLRZUIHF-GFCCVEGCSA-N 0.000 description 1
CENXXRDQDWELCL-UHFFFAOYSA-N methyl 1,2-dimethyl-6-oxopyridine-4-carboxylate Chemical compound COC(=O)C=1C=C(C)N(C)C(=O)C=1 CENXXRDQDWELCL-UHFFFAOYSA-N 0.000 description 1
HQKRJZUSDCFNHF-UHFFFAOYSA-N methyl 1-methyl-2-oxopyridine-4-carboxylate Chemical compound COC(=O)C=1C=CN(C)C(=O)C=1 HQKRJZUSDCFNHF-UHFFFAOYSA-N 0.000 description 1
YAJNNHOWKMREOO-UHFFFAOYSA-N methyl 2,6-dimethoxypyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC(OC)=NC(OC)=N1 YAJNNHOWKMREOO-UHFFFAOYSA-N 0.000 description 1
UAWGJLZPZYXSBO-UHFFFAOYSA-N methyl 2-methyl-6-oxo-1h-pyridine-4-carboxylate Chemical compound COC(=O)C=1C=C(C)NC(=O)C=1 UAWGJLZPZYXSBO-UHFFFAOYSA-N 0.000 description 1
GJLWQAUHCDNAEK-UHFFFAOYSA-N methyl 6-oxo-1h-pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(O)=N1 GJLWQAUHCDNAEK-UHFFFAOYSA-N 0.000 description 1
TWIIRMSFZNYMQE-UHFFFAOYSA-N methyl pyrazine-2-carboxylate Chemical compound COC(=O)C1=CN=CC=N1 TWIIRMSFZNYMQE-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007472 neurodevelopment Effects 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000003961 neuronal insult Effects 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
208000020629 overactive bladder Diseases 0.000 description 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
150000004866 oxadiazoles Chemical class 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
208000027753 pain disease Diseases 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
MNTZZDOKIWMNIM-UHFFFAOYSA-N phenyl cyclopropanecarboxylate Chemical compound C1CC1C(=O)OC1=CC=CC=C1 MNTZZDOKIWMNIM-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
229910000343 potassium bisulfate Inorganic materials 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008307 presynaptic mechanism Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
150000003140 primary amides Chemical class 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
OHFIJHDYYOCZME-UHFFFAOYSA-N pyrazine-2-carbohydrazide Chemical compound NNC(=O)C1=CN=CC=N1 OHFIJHDYYOCZME-UHFFFAOYSA-N 0.000 description 1
NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
JUSIWJONLKBPDU-UHFFFAOYSA-N pyridazine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NN=C1 JUSIWJONLKBPDU-UHFFFAOYSA-N 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229960001922 sodium perborate Drugs 0.000 description 1
229940056729 sodium sulfate anhydrous Drugs 0.000 description 1
229910001495 sodium tetrafluoroborate Inorganic materials 0.000 description 1
YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000000956 solid--liquid extraction Methods 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000009331 sowing Methods 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000003956 synaptic plasticity Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
KEKOWHLHSVLJLH-SSDOTTSWSA-N tert-butyl (2r)-2-(2h-tetrazol-5-yl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C1=NNN=N1 KEKOWHLHSVLJLH-SSDOTTSWSA-N 0.000 description 1
FBKDHUOQMIGIED-SECBINFHSA-N tert-butyl (2r)-2-(hydroxyiminomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@@H]1C=NO FBKDHUOQMIGIED-SECBINFHSA-N 0.000 description 1
PITJAAIPVBVRAO-SSDOTTSWSA-N tert-butyl (2r)-2-carbamoylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(N)=O PITJAAIPVBVRAO-SSDOTTSWSA-N 0.000 description 1
KZNDGAGWQPGYTB-SECBINFHSA-N tert-butyl (2r)-2-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@@H]1C=O KZNDGAGWQPGYTB-SECBINFHSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
210000001103 thalamus Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
231100000886 tinnitus Toxicity 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
MPSUGQWRVNRJEE-UHFFFAOYSA-N triazol-1-amine Chemical class NN1C=CN=N1 MPSUGQWRVNRJEE-UHFFFAOYSA-N 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000013022 venting Methods 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000004246 zinc acetate Substances 0.000 description 1
GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Psychology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0710979-2A 2006-05-05 2007-04-25 composto, composição farmacêutica, uso de um composto, métodos para a inibição de relaxamentos do esfìncter esofágico inferior transitórios e para o tratamento ou prevenção de doença e de condição, e, combinação BRPI0710979A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US79765906P	2006-05-05	2006-05-05
US60/797659		2006-05-05
PCT/US2007/067367 WO2007130820A2 (en)	2006-05-05	2007-04-25	Mglur5 modulators i

Publications (1)

Publication Number	Publication Date
BRPI0710979A2 true BRPI0710979A2 (pt)	2011-05-31

Family

ID=38668440

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0710979-2A BRPI0710979A2 (pt)	2006-05-05	2007-04-25	composto, composição farmacêutica, uso de um composto, métodos para a inibição de relaxamentos do esfìncter esofágico inferior transitórios e para o tratamento ou prevenção de doença e de condição, e, combinação

Country Status (19)

Country	Link
US (1)	US7678796B2 (es)
EP (1)	EP2027120A2 (es)
JP (1)	JP2009536209A (es)
KR (1)	KR20090009952A (es)
CN (1)	CN101506202A (es)
AR (1)	AR060651A1 (es)
AU (1)	AU2007248288A1 (es)
BR (1)	BRPI0710979A2 (es)
CA (1)	CA2650114A1 (es)
CL (1)	CL2007001174A1 (es)
CO (1)	CO6140060A2 (es)
EC (1)	ECSP088864A (es)
IL (1)	IL194814A0 (es)
MX (1)	MX2008013835A (es)
NO (1)	NO20084850L (es)
RU (1)	RU2008141509A (es)
TW (1)	TW200811157A (es)
UY (1)	UY30304A1 (es)
WO (1)	WO2007130820A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070185100A1 (en) *	2004-02-18	2007-08-09	Astrazeneca Ab	Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200821305A (en) *	2006-10-05	2008-05-16	Astrazeneca Ab	MGluR5 modulators
DE602007011793D1 (de) *	2006-10-18	2011-02-17	Pfizer Prod Inc	Biaryl-ether-harnstoffverbindungen
AU2008286879B2 (en)	2007-08-13	2013-08-22	Monsanto Technology Llc	Compositions and methods for controlling nematodes
BRPI0818448A2 (pt)	2007-10-19	2015-05-12	Astrazeneca Ab	Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.
WO2009054790A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Amide linked heteroaromatic derivatives as modulators of mglur5
TW200922585A (en) *	2007-10-26	2009-06-01	Astrazeneca Ab	Amino 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054786A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
WO2009054785A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054789A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
WO2009054791A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
WO2009054787A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
TW200922586A (en) *	2007-10-26	2009-06-01	Astrazeneca Ab	Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054792A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Aminopyridine derivatives as modulators of mglur5
CN102285914B (zh) *	2010-06-18	2013-12-25	上海药明康德新药开发有限公司	2-(1-甲基-6-羰基-1,6-二氢-吡啶)-乙酸的合成方法
JP5826848B2 (ja) *	2010-09-02	2015-12-02	モンサントテクノロジーエルエルシー	線虫を防除する新規組成物および方法
UA113223C2 (xx) *	2012-08-13	2016-12-26		Арилетинілпіримідини
GB201215033D0 (en) *	2012-08-23	2012-10-10	Novartis Ag	Diazepinone derivatives
EP2900659B1 (en) *	2012-09-27	2016-08-24	F. Hoffmann-La Roche AG	Arylethynyl derivatives
US9173401B2 (en)	2013-03-15	2015-11-03	Monsanto Technology Llc	N-,C-disubstituted azoles and compositions and methods for controlling nematode pests
EP2857387A1 (en)	2013-10-07	2015-04-08	Boehringer Ingelheim International Gmbh	Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid
MY202326A (en) *	2017-09-14	2024-04-24	Daiichi Sankyo Co Ltd	Compound having cyclic structure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7074809B2 (en)	2002-08-09	2006-07-11	Astrazeneca Ab	Compounds
WO2004014881A2 (en)	2002-08-09	2004-02-19	Astra Zeneca Ab	'1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
TW200424183A (en)	2002-08-09	2004-11-16	Nps Pharma Inc	New compounds
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
WO2005077368A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Compounds for the treatment of gastro-esophageal reflux disease
WO2005080356A1 (en)	2004-02-18	2005-09-01	Astrazeneca Ab	Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
US20070185100A1 (en)	2004-02-18	2007-08-09	Astrazeneca Ab	Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US7585881B2 (en)	2004-02-18	2009-09-08	Astrazeneca Ab	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE602005008558D1 (de)	2004-02-18	2008-09-11	Astrazeneca Ab	Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
WO2006048771A1 (en)	2004-11-04	2006-05-11	Addex Pharmaceuticals Sa	Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0514296D0 (en)	2005-07-12	2005-08-17	Novartis Ag	Organic compounds

2007
- 2007-04-24 TW TW096114401A patent/TW200811157A/zh unknown
- 2007-04-25 UY UY30304A patent/UY30304A1/es not_active Application Discontinuation
- 2007-04-25 WO PCT/US2007/067367 patent/WO2007130820A2/en not_active Ceased
- 2007-04-25 CA CA002650114A patent/CA2650114A1/en not_active Abandoned
- 2007-04-25 EP EP07761248A patent/EP2027120A2/en not_active Withdrawn
- 2007-04-25 MX MX2008013835A patent/MX2008013835A/es not_active Application Discontinuation
- 2007-04-25 AR ARP070101781A patent/AR060651A1/es unknown
- 2007-04-25 AU AU2007248288A patent/AU2007248288A1/en not_active Abandoned
- 2007-04-25 RU RU2008141509/04A patent/RU2008141509A/ru not_active Application Discontinuation
- 2007-04-25 CL CL2007001174A patent/CL2007001174A1/es unknown
- 2007-04-25 KR KR1020087029720A patent/KR20090009952A/ko not_active Withdrawn
- 2007-04-25 CN CNA2007800252941A patent/CN101506202A/zh active Pending
- 2007-04-25 BR BRPI0710979-2A patent/BRPI0710979A2/pt not_active IP Right Cessation
- 2007-04-25 JP JP2009509953A patent/JP2009536209A/ja active Pending
- 2007-04-25 US US11/790,417 patent/US7678796B2/en not_active Expired - Fee Related
2008
- 2008-10-22 IL IL194814A patent/IL194814A0/en unknown
- 2008-10-30 CO CO08116342A patent/CO6140060A2/es unknown
- 2008-11-05 EC EC2008008864A patent/ECSP088864A/es unknown
- 2008-11-18 NO NO20084850A patent/NO20084850L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
UY30304A1 (es)	2007-11-30
RU2008141509A (ru)	2010-06-20
NO20084850L (no)	2008-12-02
KR20090009952A (ko)	2009-01-23
CA2650114A1 (en)	2007-11-15
AR060651A1 (es)	2008-07-02
IL194814A0 (en)	2009-08-03
JP2009536209A (ja)	2009-10-08
CN101506202A (zh)	2009-08-12
AU2007248288A1 (en)	2007-11-15
MX2008013835A (es)	2008-11-10
CO6140060A2 (es)	2010-03-19
EP2027120A2 (en)	2009-02-25
TW200811157A (en)	2008-03-01
WO2007130820A3 (en)	2008-03-13
US20070259862A1 (en)	2007-11-08
WO2007130820A2 (en)	2007-11-15
ECSP088864A (es)	2008-12-30
US7678796B2 (en)	2010-03-16
CL2007001174A1 (es)	2008-01-18

Legal Events

Date	Code	Title	Description
2012-06-05	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 5A ANUIDADE.
2012-11-13	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 5A ANUIDADE.

Publication	Publication Date	Title
BRPI0710979A2 (pt)	2011-05-31	composto, composição farmacêutica, uso de um composto, métodos para a inibição de relaxamentos do esfìncter esofágico inferior transitórios e para o tratamento ou prevenção de doença e de condição, e, combinação
AU2007303889B2 (en)	2011-02-24	mGluR5 modulators
US20070259926A1 (en)	2007-11-08	mGluR5 modulators III
KR20070052693A (ko)	2007-05-22	폴리헤테로시클릭 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도
BRPI0710980A2 (pt)	2011-05-31	composto, composição farmacêutica, uso de um composto, métodos para a inibição de relaxamentos do esfìncter esofágio inferior transitórios, para o tratamento ou prevenção de uma doença ou condição, e, combinação
US20090111824A1 (en)	2009-04-30	Amide linked heteroaromatic derivatives as modulators of mglur5
US20070259923A1 (en)	2007-11-08	MGluR5 modulators IV
US20070259916A1 (en)	2007-11-08	mGluR5 modulators II
US20090111820A1 (en)	2009-04-30	Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
US20090111825A1 (en)	2009-04-30	Thiophene 1,2,4-triazole derivatives as modulators of mglur5
US20090111822A1 (en)	2009-04-30	1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
US20090111854A1 (en)	2009-04-30	1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
US20090111823A1 (en)	2009-04-30	Aminopyridine derivatives as modulators of mglur5